Currently Viewing:
Supplements Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin
Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors
Murray Epstein, MD; Nancy L. Reaven, MA; Susan E. Funk, MBA; Karen J. McGaughey, PhD; Nina Oestreicher, PhD; John Knispel, MD
eAPPENDIX 1. ICD-9 CODES USED FOR CLASSIFICATION OF COMORBIDITIES
eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS
eAPPENDIX 3. ADVERSE OUTCOME DEFINITIONS
Currently Reading
Participating Faculty: Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

Participating Faculty: Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

This supplement to The American Journal of Managed Care describes a study that examined reninangiotensin- aldosterone system (RAAS) inhibitor dose levels in a US patient population, investigated the impact of hyperkalemia on RAAS inhibitor dose, and evaluated the association between dose levels and clinical outcomes. The results show that relatively few patients were prescribed maximum doses of RAAS inhibitors, and dose and usage declined following hyperkalemia. Patients on submaximum doses or who discontinued RAAS inhibitors had worse outcomes than patients on maximum doses.
This study and publication were sponsored by Relypsa, Inc.
 

Faculty
 
Murray Epstein, MD
Professor of Medicine
Division of Nephrology and Hypertension
University of Miami Miller School of Medicine
Miami, Florida

Medical Investigator
South Florida VA Research and Education Foundation
VA Medical Center
Miami, Florida

Susan E. Funk, MBA
Senior Vice President of Data Analytics
Strategic Health Resources
La Cañada, California

John Knispel, MD
Regional Medical Director, Florida
Humana Inc
West Palm Beach, Florida

Karen J. McGaughey, PhD
Associate Professor
Department of Statistics
California Polytechnic State University
San Luis Obispo, California

Nina Oestreicher, PhD
Executive Director
Health Economics and Outcomes Research
Relypsa, Inc
Redwood City, California

Assistant Clinical Professor
University of California, San Francisco
Department of Clinical Pharmacy
San Francisco, California

Nancy L. Reaven, MA
President
Strategic Health Resources
La Cañada, California


Faculty Disclosures

These faculty report relationships with the following organizations:

Murray Epstein, MD
Consultant or paid advisory board: Bayer; OPKO Health; Relypsa, Inc
Lecture fees/meeting conference attendance: Relypsa, Inc

Susan E. Funk, MBA
Consultant/receipt of payment for involvement in preparation of this manuscript: Relypsa, Inc; Strategic Health Resources

John Knispel, MD
Consultant/receipt of payment for involvement in preparation of this manuscript: Relypsa, Inc

Karen J. McGaughey, PhD
Consultant:
Relypsa, Inc; Strategic Health Resources

Nina Oestreicher, PhD
Employment/stock ownership: Relypsa, Inc

Nancy L. Reaven, MA
Consultant: Relypsa, Inc; Strategic Health Resources
Stock ownership: Relypsa, Inc

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up